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ABSTRACT
BACKGROUND AND PURPOSE: Attempts have been made to quantify the microvascular leakiness of glioblastomas and use it as an
imaging biomarker to predict the prognosis of the tumor. The purpose of our study was to evaluate whether the extraction frac-
tion value from DSC-MR imaging within nonenhancing FLAIR hyperintense lesions was a better prognostic imaging biomarker than
dynamic contrast-enhanced MR imaging parameters for patients with glioblastoma.
MATERIALS AND METHODS: A total of 102 patients with glioblastoma who received a preoperative dynamic contrast-enhanced MR
imaging and DSC-MR imaging were included in this retrospective study. Patients were classified into the progression (n = 87) or non-
progression (n = 15) groups at 24months after surgery. We extracted the means and 95th percentile values for the contrast leakage
information parameters from both modalities within the nonenhancing FLAIR high-signal-intensity lesions.
RESULTS: The extraction fraction 95th percentile value was higher in the progression-free survival group of .24months than at
#24months. The median progression-free survival of the group with an extraction fraction 95th percentile value of .13.32 was
17months, whereas that of the group of #13.32 was 12months. In addition, it was an independent predictor variable for progres-
sion-free survival in the patients regardless of their ages and genetic information.
CONCLUSIONS: The extraction fraction 95th percentile value was the only independent parameter for prognostic prediction in
patients with glioblastoma among the contrast leakage information, which has no statistically significant correlations with the DCE-
MR imaging parameters.
ABBREVIATIONS: DCE 4 dynamic contrast-enhanced; EF 4 extraction fraction; Ktrans 4 volume transfer constant; MGMT 4 O6-methylguanine methyl-
transferase; PFS 4 progression-free survival; Ve 4 volume of extravascular extracellular space; Vp 4 volume of vascular plasma space; IDH 4 isocitrate
dehydrogenase
G lioblastoma multiforme is a hypervascular tumor, and itsaggressive portion is known to disrupt the BBB, resulting in
enhancement on contrast-enhanced MR imaging. In addition,
glioblastoma tumor cells have an infiltrative nature that shows
only high signal intensity on FLAIR images without definite
enhancement. This characteristic of the tumor is highly related to
microvasculature disruption, which may be demonstrated as BBB
leakiness.1-3 The standard treatment for glioblastoma is surgical
resection, followed by concomitant chemoradiotherapy with adju-
vant temozolomide.4,5 The surgical resection is performed mainly
at the contrast-enhancing portion of the tumor based on imaging
guidance. Nonenhancing infiltrative tumor cells remain after the
operation, which explains most of the local recurrences at the
Received June 18, 2019; accepted after revision September 16.
From the Departments of Radiology (S.H.K., K.H.C., S.H.C.), Pathology (S.H.P., J.K.W.),
and Neurology (S.T.L.), Seoul National University College of Medicine, Seoul,
Korea; Center for Nanoparticle Research (S.H.C.), Institute for Basic Science, Seoul,
Korea; School of Chemical and Biological Engineering (S.H.C.), Seoul National
University, Seoul, Korea; Departments of Internal Medicine (T.M.K.) and Radiation
Oncology (I.H.K.), Cancer Research Institute, Seoul National University College of
Medicine, Seoul, Korea; and Department of Neurosurgery (C.K.P.), Biomedical
Research Institute, Seoul National University College of Medicine, Seoul, Korea.
S.H. Kim and K.H. Cho contributed equally to this work.
This study was supported by a grant from the Korea Healthcare Technology R&D
Projects, Ministry for Health, Welfare & Family Affairs (HI16C1111), by the Bio &
Medical Technology Development Program of the National Research Foundation of
Korea funded by the Korean government, Ministry of Science, Information &
Community Technology and Future Planning (NRF-2015M3A9A7029740), by the Brain
Research Program through the National Research Foundation of Korea funded by
the Ministry of Science, Information & Community Technology and Future Planning
(2016M3C7A1914002), by the Creative-Pioneering Researchers Program through Seoul
National University, and by Project Code (IBS-R006-D1).
Please address correspondence to Seung Hong Choi, MD, PhD, Department of
Radiology, Seoul National University College of Medicine, 28, Yongon-dong,
Chongno-gu, 110-744, Seoul, Korea; e-mail: verocay@snuh.org
Indicates open access to non-subscribers at www.ajnr.org
Indicates article with supplemental on-line appendix and tables.
Indicates article with supplemental on-line photos.
http://dx.doi.org/10.3174/ajnr.A6297
2052 Kim Dec 2019 www.ajnr.org
resection margin.6 Those infiltrative tumor cells intermingle
with reactive edema on T2WI or T2 FLAIR images, thereby
increasing the difficulty of their identification. Therefore, non-
enhancing FLAIR high-signal-intensity lesions have clinical
significance.7
Attempts have been made to quantify the microvascular leaki-
ness of a tumor and use it as a biomarker to predict the level of
aggressiveness and the prognosis of a tumor. One approach is the
use of dynamic contrast-enhanced (DCE) MR imaging, which is
an imaging technology that provides BBB permeability informa-
tion, to analyze nonenhancing FLAIR high-signal-intensity
lesions of glioblastoma.8 Gliomas with high-permeability param-
eters from DCE-MR imaging have been reported to show a poor
prognosis due to a large proportion of leaky vasculature.9-11 To
date, many studies have revealed the utility of DCE-MR imaging
for predicting the tumor grade and/or tumor progression in
patients with glioblastoma.12
Recently, a new method that can reveal contrast leakage infor-
mation (ie, the extraction fraction [EF]) using DSC-MR imaging
has been reported; this method has well-known advantages over
DCE-MR imaging, such as providing perfusion information, a
shorter scan time, and higher contrast.13 However, no studies
have investigated the application of EF for prognostication in
patients with glioblastoma receiving standard treatment. Thus,
the aim of our study was to evaluate whether the EF parameter
from DSC-MR imaging has correlation with contrast leakage in-
formation from DCE-MR imaging and whether the EF value
from nonenhancing FLAIR high-signal-intensity lesions was a
better prognostic imaging biomarker than DCE-MR imaging




This retrospective study was approved by the Institutional
Review Board of Seoul National University Hospital. The require-
ment for informed consent was waived. A total of 134 patients
diagnosed with glioblastoma from April 2010 to September 2018
at Seoul National University Hospital were enrolled in this study.
The following were the inclusion criteria: adult patients (older
than 18 years of age) who were initially diagnosed with glioblas-
toma based on the 2016 World Health Organization classification
of central nervous system tumors, underwent both preoperative
DCE- and DSC-MR imaging, and received the standard treat-
ment, including surgical resection of the contrast-enhancing
lesion, followed by concomitant chemoradiotherapy with temo-
zolomide and adjuvant temozolomide. Patients with lost raw data
(n=14) or inadequate image quality for analysis (n=17) or who
were lost to follow-up (n=1) were excluded from the study.
Under these inclusion and exclusion criteria, 102 patients were
enrolled in our study.
All patients underwent a follow-up MR imaging while visiting
the outpatient clinic. On the basis of the clinical features and
radiologic results, we categorized our study population into dis-
ease progression and nonprogression groups according to the
Response Assessment in Neuro-Oncology criteria at 24months
after the operation. Patients satisfying any of the following
Response Assessment in Neuro-Oncology criteria were consid-
ered to have disease progression14: 1) a .25% increase in the
sum of the products of the perpendicular diameters of the
enhancing lesions with the smallest tumor measurement, 2) any
new lesion, 3) clear clinical deterioration not attributable to
causes other than the tumor, and 4) clear progression of nonmea-
surable disease. Accordingly, 15 patients (14.7%) were grouped
into the nonprogression group, and 87 patients (85.3%) were
classified into the disease-progression group.
The flow diagram in On-line Fig 1 shows the inclusion and
exclusion of patients in this study. Image acquisition is summar-
ized in the On-line Appendix.
Image Processing and Analysis
MR images were acquired from the PACS workstation and
transferred to a personal computer using a software package
(NordicICE, Version 4.1.2; Nordic-NeuroLab, Bergen, Norway)
for analysis. On-line Figure 2 shows the schematic diagram of the
imaging analysis.
The DCE and DSC perfusion MR imaging analysis methods
based on the 2-compartment pharmacokinetic model were per-
formed with the DCE- and DSC-MR imaging data to calculate
contrast leakage information parameters, which were presented
as parametric maps. The parameters of interest were volume
transfer constant (Ktrans), volume of extravascular extracellular
space (Ve), volume of vascular plasma space (Vp), and EF.15 For
preprocessing, the noise threshold and noise level were set to dis-
pose of noise during parameter extraction from the MR imaging.
In addition, a motion-correction function was used for spatial
and temporal smoothing of the MR imaging. After preprocessing,
vascular deconvolution with the arterial input function was exe-
cuted by determining it in the intracranial tumor-supplying
arteries near the tumor for DCE-MR imaging. This step was
assisted by the software’s automatic detection function for arterial
input function, which still required manual setting of the arterial
input function search region within the tumor. Subsequently, the
arterial input function curves and concentration-time curve were
generated, which indicated the tumor-supplying artery within the
ROI. To find the ideal relationship between the arterial input
function curve and the concentration-time curve, we manually
defined the ROI, and an appropriate arterial input function curve
was selected by 2 well-trained medical students (S.H.K. and
K.H.C.) supervised by 1 neuroradiologist (S.H.C., with 16 years of
experience in brain MR imaging). The baseline T1 was fixed at
1000 ms in this study.16
A recently introduced contrast leakage information parameter
(EF) from DSC-MR imaging is defined as the ratio of permeabil-
ity (Ktrans) to perfusion (fractional tissue perfusion). EF describes
the fraction of contrast agent that is extracted during the first pas-
sage through tissue following an instantaneous tracer bolus.
Assisted by automated arterial input function detection, EF is
obtained by a novel contrast agent extravasation-correction
method that is based on fitting the tissue residue function, includ-
ing both apparent tissue extravasation and a perfusion compo-
nent, to the 2-compartment uptake kinetic model.17-20 Both the
arterial input function and the tissue residue function were esti-
mated from the T1- and T2*-dominant leakage effect. Then, the
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value of F derived from the tissue residue function was applied to
the equation to calculate the EF.17,21
A multiplanar reconstruction tool was used to convert con-
trast-enhanced, T1-weighted, multiplanar images into axial
images. These axial contrast-enhanced T1WI and FLAIR images
were deployed for structural imaging. The coregistration algo-
rithm of the software allows users to resample the number of
target image sets to that of a reference image set based on the
geometric information stored in each dataset. In our case, the
target image set was structural images, whereas the reference
image set was parametric maps from the DCE- and DSC-MR
imaging.22,23
Afterwards, the parametric maps were coregistered with the
structural images from the FLAIR and contrast-enhanced
T1WI. Then, the ROIs of the nonenhancing FLAIR high-
signal-intensity lesion on each axial image were determined
manually by reviewers blinded to any information regarding
the patient’s prognosis. Additionally, the necrotic and cystic
regions as well as large vessels were excluded from the ROI. All
manual tasks were performed by consensus to minimize
reviewer bias.
We used the ROI analysis function provided by the software
to calculate the contrast leakage information, including the Ktrans,
Vp, Ve, and EF, from every pixel within the range of the ROI on
every axial image and thereby acquired the sum of values from all
pixels in the ROI. The total parametric values from the entire
nonenhancing FLAIR high-signal-intensity lesion were obtained
for each tumor. Finally, the mean values and 95th percentile val-
ues for Ktrans, Vp, Ve, and EF were derived from the cumulative
histograms (the xth percentile point is the point at which x% of
the pixel values that form the histogram are found to the left of
the histogram).
Statistical Analysis
All statistical analyses were performed by using MedCalc for
Windows, Version 18.11 (MedCalc Software, Mariakerke,
Belgium). For all analyses, only P, .05 was considered statisti-
cally significant. Clinical characteristics, including age, sex, date
of the operation, radiation dose, date of progression, and genetic
information, were recorded for each patient. The Fisher exact
test was performed for categoric data. The data for each parame-
ter were assessed for normality with the Kolmogorov-Smirnov
test. An unpaired Student t test was performed to compare data
between the disease progression and nonprogression groups, in
which patients with a follow-up period of .24months or pro-
gression-free survival (PFS) of#24months were enrolled.
The Pearson correlation analysis for parametric data was
performed to assess the correlations between the EF from
DSC-MR imaging and contrast leakage information (eg, Ktrans,
Ve, and Vp) from DCE-MR imaging, which were obtained
from contrast-enhancing areas as well as nonenhancing FLAIR
high-signal-intensity lesions. To further assess the correla-
tion analysis, we calculated intraclass correlation coefficients.
Intraclass correlation coefficient values of ,0, 0–0.2.0, 0.21–
0.40, 0.41–0.60, 0.61–0.80, or .0.81 were interpreted as nega-
tive, positive but poor, fair, moderate, good, or excellent agree-
ment, respectively.
Receiver operating characteristic curve analysis was per-
formed to set the optimum cutoff value for each contrast leak-
age parameter with an aim of distinguishing between the
disease progression and nonprogression groups and to calcu-
late the diagnostic performances of the contrast leakage
information.
PFS was assessed using the Kaplan-Meier method according
to the contrast leakage information and was compared using the
log-rank test. We only recorded the first progression. PFS was
calculated from the date of the operation to that of glioblastoma
progression, the patient’s death, the last confirmation of no evi-
dence of disease, or the most recent follow-up examination.
Patients without an event were censored at the date of the most
recent follow-up regardless of whether they were scheduled for
future follow-ups or had been lost to follow-up. Receiver operat-
ing characteristic curve analysis was performed to determine the
thresholds for each contrast leakage information parameter for
PFS. Multivariate analysis was performed using the Cox propor-
tional hazards model adjusted for prognostic factors, including
age, the isocitrate dehydrogenase (IDH) 1/2mutation, and the O6-
methylguanine methyltransferase (MGMT) promoter methylation
status.
Finally, the prediction performance of the 95th percentile
EF was evaluated via the leave-one-out method. This method
was performed by selecting 1 patient as a testing sample, with
the remaining patients used as the training samples. The cutoff
values determined by receiver operating characteristic curve
analysis on the training samples were used to distinguish
whether the testing sample belonged to the early disease pro-
gression or the nonprogression group. As a result of these vali-
dation rounds, we acquired the sensitivity, specificity, and




The mean age of the patients with glioblastoma in the disease
progression group (n=87) was slightly higher than that of the
patients in the nonprogression group (n=15) (59.246 13.50 ver-
sus 51.33 6 13.96 years, respectively, P= .04). The other clinical
characteristics, including the radiation dose, sex, MGMT promo-
tor methylation status and IDH 1/2 mutation status, were not
statistically significantly different between the 2 groups (all,
P. .05; Table 1).
Correlation analyses between EF from DSC-MR imaging and
contrast leakage information from DCE-MR imaging are given in
the On-line Appendix and On-line Fig 3.
Comparison of Contrast Leakage Information and
Imaging Findings between the Early Disease Progression
and Nonprogression Groups
These analyses enrolled patients with a follow-up period of
.24months without progression (n=15) or PFS of#24months
(n=71), as mentioned above. On the basis of the unpaired
Student t test, the EF 95th percentile value was higher for the
patients in the nonprogression group than for those in the
disease-progression group (15.7895% 6 8.6931% versus
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11.0527% 6 7.6511%, respectively, P = .0363). However, no
statistically significant differences in the other parameters
were found between the 2 groups (all, P. .05; Table 2).
Here, sensitivity and specificity are defined for identification
of early disease progression and nonprogression, respectively,
using receiver operating characteristic curve analysis. The EF
95th percentile value also showed statistical significance in re-
ceiver operating characteristic curve analysis, with an area under
curve of 0.71 (95% CI, 0.599–0.800, and P= .008). The best cutoff
criterion for the EF 95th percentile value was 13.32, with a sensi-
tivity of 60.0% and a specificity of 78.9%. Two representative
cases with disease progression and nonprogression with paramet-
ric maps of EF, Ktrans, Ve, and Vp are shown in Figs 1 and 2,
respectively.
Correlation analysis between the EF from DSC-MR imaging
and contrast leakage information fromDCE-MR imaging is given
in the On-line Appendix and On-line Table 1.
Leave-One-Out Cross-Validation
In the leave-one-out cross-validation of the EF 95th percentile
value, the cross-validated values for the prediction of glioblas-
toma disease progression were found, with corresponding sensi-
tivity (46.67%), specificity (77.46%), and accuracy (72.09%).
Contrast Leakage Information Correlated with PFS. In all
patients, PFS was correlated with the EF 95th percentile value
with an optimum cutoff value of 13.32% obtained from receiver
operating characteristic curve analysis, which showed statistical
significance (P = 0.02) (On-line Fig 4).
Then, we performed Cox proportional
hazards model analysis, including the
EF 95th percentile value, which was
significantly associated with PFS, and
previously reported prognostic genetic
factors, including the IDH1/2 muta-
tion and MGMT promotor methyla-
tion status. The analysis revealed that
only the EF 95th percentile value
was significant among these factors
(P = .01, On-line Table 2). In all
patients, a significant difference in PFS
was found between patients with high
and low EF 95th percentile values (me-
dian, 17.0 months [95% CI, 12.0–36.0
months] versus 12.0 months [95% CI,
9.0–15.0 months]; P= .02, log-rank test),
which was independent of age, the
IDH1/2 mutation, and the MGMT pro-
motor methylation status.
DISCUSSION
In our study, contrast leakage infor-
mation from both DCE- and DSC-MR
imaging, including the EF, Ktrans, Ve,
and Vp, was analyzed for prognostica-
tion in patients with glioblastoma
treated with standard methods. Most
interesting, the EF value from DSC-
MR imaging had no significant










Mean age (yr) 56.9 59.2 6 13.5 51.3 6 14.0 .04b
Mean radiation dose (Gy) 51.9 52.5 6 18.4 48.6 6 0.6 .43b
Sex .40c
Male 59 52 7
Female 43 35 8
Methylated MGMT promoter .09c
Positive 59 47 12
Negative 42 39 3
IDH1/2 mutation .28c
Positive 7 5 2
Negative 94 81 13
a Unless otherwise specified, data are given as the number of patients.
b Calculated with an unpaired Student t test.
c Calculated with the Fisher exact test.
Table 2: Comparison of the parametric values of the progression and nonprogression
groupsa
Parameters Progression (n = 71) Nonprogression (n = 15) P Valueb
Mean tumor volume (mL) 119.84 6 85.65 161.81 6 102.59 .10
EF 95th PV (%) 11.053 6 7.651 15.790 6 8.693 .04
EF mean (%) 2.473 6 1.552 3.140 6 1.463 .13
Ktrans 95th PV (min–1) 0.140 6 0.118 0.177 6 0.132 .28
Ktrans mean (min–1) 0.022 6 0.024 0.0260 6 0.021 .59
Ve 95th PV 51.604 6 71.965 44.480 6 29.773 .71
Ve mean 7.750 6 16.050 6.209 6 4.917 .71
Vp 95th PV 5.334 6 5.488 6.594 6 4.807 .41
Vp mean 1.264 6 1.352 1.384 6 0.100 .75
Note:—PV indicates percentile value.
a Patients with a follow-up period of .24months without progression (n = 15) or PFS of #24months (n = 71) were
analyzed.
b Calculated with an unpaired Student t test.
FIG 1. A 64-year-old patient with glioblastoma who had early disease progression (PFS = 14months) after standard treatment. The preoperative
axial contrast-enhanced T1WI (A) and FLAIR (B) images represent an enhancing area and nonenhancing FLAIR high-signal-intensity lesions, respec-
tively. The preoperative parametric maps of contrast leakage information (EF, Ktrans, Ve, and Vp) are shown (C, D, E, and F, respectively). A low EF
value on the nonenhancing FLAIR high-signal-intensity lesion was observed, with an EF 95th percentile value of 5.67.
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correlation with any DCE-MR imaging parameters. We found
that the EF 95th percentile value was higher in patients with non-
progression than in patients with disease progression within
2 years. We also found that patients with a higher EF 95th percen-
tile value had longer PFS than those with a lower value. PFS also
had a significant correlation with the EF 95th percentile value,
which was the most important prognostic marker, regardless of
age, IDH1/2 mutation, and the MGMT promoter methylation
status.
Microscopic infiltrative glioblastoma cells commonly are
unenhanced on contrast-enhanced T1WI and are indistinguish-
able from peritumoral edema components, features increasing
the difficulty of response prediction for patients with glioblas-
toma. DCE- and DSC-MR imaging have been used to evaluate
microscopic infiltrative glioblastoma cells in nonenhancing
FLAIR high-signal-intensity lesions.8,24 DCE-MR imaging pa-
rameters, including the Ktrans, Ve, and Vp, can reflect vascular
permeability, which usually is increased in the glioblastoma
vasculature.10-12,25 Extensive studies have been performed to
determine the survival-associated parameters of DCE-MR
imaging in patients with glioblastoma. Despite some contro-
versies, patients with glioblastoma with high contrast leakage
information parameters on DCE-MR imaging are known to
have a poor prognosis.26-30 However, no controlled studies
have been established to evaluate the EF on the basis of DSC-
MR imaging as a survival-associated parameter.
In our study, although a weak correlation was found between
the mean EF and Vp values in the Pearson correlation analysis,
no statistical correlation was found with the other parameters,
and the intraclass correlation coefficients did not show any signif-
icant correlations between the EF and the DCE-MR imaging pa-
rameters. These results are supported by previous studies in
patients with glioblastoma that indicated a nonlinear relationship
between the Ktrans obtained from DCE-MR imaging and that
obtained by DSC-MR imaging, probably due to the mixed contri-
butions from the T1- and T2*-dominant leakage effects in DSC-
MR imaging.13,21 Even for the EF, because the estimation of
perfusion theoretically is independent of leakage, varying contri-
butions of the 2 relaxation effects by postextravasation would
directly influence the magnitude of the resulting EF value.
Therefore, even though both DCE- and DSC-MR imaging use a
contrast agent extravasation-correction method, the EF para-
meter from DSC-MR imaging cannot replace the parameters
from DCE-MR imaging; however, the EF may be a noteworthy
parameter that is affected by the T2* effect from contrast agents
and may be more sensitive to contrast leakage than the parame-
ters that are mainly determined by the T1 effect from DCE-MR
imaging.
We believe that the EF value needs clinical validation before
use as a potential imaging biomarker for prognostication in
patients with glioblastoma treated with a standard method.
Contrast leakage information can be translated into drug-delivery
predictions, especially within nonenhancing FLAIR high-signal-
intensity lesions after near-complete resection of the enhancing
portions. In nonenhancing FLAIR high-signal-intensity lesions in
patients with glioblastoma after the operation, the BBB is still an
effective barrier that prevents entry of the drug into the brain
tissue; hence, BBB disruption accounts for a better prognosis
of patients with glioblastoma due to more efficient drug deliv-
ery.31-34 The improved tumor response to chemotherapy after
radiation-induced vascular damage also supports the association
between permeability and drug delivery.35 We found that a high
EF within nonenhancing FLAIR high-signal-intensity lesions was
an independent prognostic biomarker for longer PFS in patients
with glioblastoma in our study, which suggested that the EF value
could effectively reflect BBB disruption related to the chemother-
apy response.
The MGMT gene encodes the MGMT protein, which has
DNA repair activity.36,37 Some studies have shown a significant
correlation between theMGMT promotor methylation status and
the outcome of alkylating chemotherapeutic substances, such as
temozolomide.38 Additionally, mutations of the IDH1/2 gene
encoding the cytosolic nicotinamide adenine dinucleotide
phosphateþ–dependent isocitrate dehydrogenase have been
shown to be correlated with the outcome in patients with ma-
lignant gliomas.39,40 To examine whether these genetic statuses
influence PFS as confounding factors of the EF 95th percentile
value, we performed Cox proportional hazards regression anal-
ysis in our study. The analysis revealed that the EF 95th per-
centile value was a predictive parameter of PFS independent of
MGMT promoter methylation and the IDH1/2 mutation status
in patients with glioblastoma. Some studies have shown that
decreased vascular permeability can cause treatment resistance
in patients with gliomas.41 Similarly, in our study, improved
drug delivery by increased vascular permeability in patients
with glioblastoma could have resulted in a better prognosis
regardless of genetic variances.
Our study has some limitations, including the nature of its
retrospective design. First, the patients with glioblastoma in our
study were not perfectly balanced because the mean age of the
FIG 2. A 60-year-old patient with glioblastoma who had nonprogression (PFS = 31months) after standard treatment. The preoperative axial con-
trast-enhanced T1WI (A) and FLAIR (B) images represent an enhancing area and a nonenhancing FLAIR high-signal-intensity lesion, respectively.
The preoperative parametric maps of contrast leakage information (EF, Ktrans, Ve, and Vp) are shown (C, D, E, and F, respectively). A high EF value
on a nonenhancing FLAIR high-signal-intensity lesion was noted, with an EF 95th percentile value of 16.69.
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disease-progression group was slightly older than that of the non-
progression group, whereas no significant differences were found
in any of the other clinical characteristics. However, according to
Cox proportional hazards regression, the age of the patients with
glioblastoma did not affect the significance of the EF 95th percen-
tile value. Second, we manually marked the nonenhancing FLAIR
high-signal-intensity lesions as ROIs using image-analysis soft-
ware, which might have resulted in observer bias. However, we
carefully drew the ROIs under supervision of an expert neurora-
diologist. Third, our study enrolled patients who received a dou-
ble dose of contrast medium for both DSC- and DCE-MR
imaging. This could increase the risk of nephrogenic systemic fi-
brosis and gadolinium organ tissue deposition.42,43 Although a
macrocyclic gadolinium-based contrast agent was used in our
study, the risk of tissue deposition could be increased in patients
given a double dose of contrast material. In a previous study, 1
dose of contrast medium was suggested for the acquisition of
both DSC- and DCE-MR imaging by splitting the dose, which
was not considered in our MR imaging protocol.44 However, our
study showed the feasibility of the contrast leakage information
from DSC-MR imaging, which is usually calculated from DCE-
MR imaging; thus, our results can give evidence to reduce
unnecessary additional contrast media injections in the future.
Finally, we did not analyze the tumor tissues to find pathophysio-
logic evidence for why the EF parameter was associated with the
prognosis in patients with glioblastoma. Thus, we believe that
future studies are warranted.
CONCLUSIONS
The EF 95th percentile value within the nonenhancing FLAIR
high-signal-intensity lesions from DSC-MR imaging was the only
independent parameter for prognostication in patients with glio-
blastoma among the contrast leakage information, which has no
significant correlations with the DCE-MR imaging parameters.
Application of the EF 95th percentile value can be helpful for
treatment stratification in patients with glioblastoma.
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